MarketCap
Atossa Therapeutics ATOS
$ 2.04
-7.69%
Facebook
X
Telegram
Atossa Therapeutics Long Term Debt Current | ATOS
Annual Long Term Debt Current Atossa Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 18.1 K | 39.4 K | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.4 K | 18.1 K | 28.7 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Prelude Therapeutics Incorporated
PRLD
|
2.74 M | $ 3.8 | 1.06 % | $ 292 M |  USA |
 |
ProQR Therapeutics N.V.
PRQR
|
1.54 M | $ 1.26 | -3.82 % | $ 133 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
2.82 M | $ 6.66 | 0.68 % | $ 1.25 B | USA |
 |
PolyPid Ltd.
PYPD
|
1.16 M | $ 6.56 | 3.96 % | $ 107 M |  Israel |
 |
Outlook Therapeutics
OTLK
|
58.9 K | $ 0.48 | 4.34 % | $ 16.7 M | USA |
 |
uniQure N.V.
QURE
|
3.86 M | $ 24.64 | 8.5 % | $ 1.42 B | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
12 M | $ 16.7 | 3.44 % | $ 1.65 B | USA |
 |
Sarepta Therapeutics
SRPT
|
11.2 M | $ 16.67 | 1.4 % | $ 1.67 B | USA |
 |
REGENXBIO
RGNX
|
8.29 M | $ 8.57 | 11.38 % | $ 442 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
614 K | $ 44.17 | 0.58 % | $ 794 M | USA |
 |
SELLAS Life Sciences Group
SLS
|
544 K | $ 8.41 | 0.5 % | $ 917 M | USA |
 |
Celsion Corporation
CLSN
|
406 K | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
21.9 M | - | - | $ 866 M |  China |
 |
Tenax Therapeutics
TENX
|
107 K | $ 1.7 | 0.3 % | $ 66.7 M | USA |
 |
CureVac N.V.
CVAC
|
5.32 M | - | - | $ 867 M |  Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
8.5 M | - | - | $ 4.9 B |  Britain |
 |
Rezolute
RZLT
|
658 K | $ 4.09 | 1.74 % | $ 425 M | USA |
 |
Tiziana Life Sciences PLC
TLSA
|
106 K | $ 0.62 | 1.33 % | $ 66.1 M | Britain |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
539 K | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
784 K | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
2.58 M | $ 1.61 | -0.31 % | $ 88.9 M | USA |
 |
Gracell Biotechnologies
GRCL
|
17.5 M | - | - | $ 3.37 B | China |
 |
Shattuck Labs
STTK
|
837 K | $ 5.04 | 3.61 % | $ 351 M | USA |
|
Silence Therapeutics plc
SLN
|
179 K | $ 19.78 | -0.05 % | $ 2.8 B | Britain |
 |
Stoke Therapeutics
STOK
|
3.01 M | $ 27.75 | 1.98 % | $ 1.64 B | USA |
 |
Sutro Biopharma
STRO
|
7.78 M | $ 10.25 | 0.79 % | $ 87.1 M | USA |
 |
Soligenix
SNGX
|
114 K | $ 0.32 | 0.37 % | $ 1.66 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
288 M | $ 43.19 | 1.85 % | $ 49.5 B | Israel |
 |
China SXT Pharmaceuticals
SXTC
|
8.78 K | $ 2.96 | 2.78 % | $ 2.01 M | China |
 |
Spruce Biosciences
SPRB
|
317 K | $ 46.52 | -0.32 % | $ 35.7 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
10.6 M | $ 29.29 | 1.88 % | $ 1.65 B | USA |
 |
Galapagos NV
GLPG
|
1.73 M | - | - | $ 1.83 B | Belgium |
 |
Savara
SVRA
|
200 K | $ 5.03 | 2.24 % | $ 1.12 B | USA |
 |
TG Therapeutics
TGTX
|
1.04 M | $ 65.76 | 2.33 % | $ 9.49 B | USA |
 |
Trevi Therapeutics
TRVI
|
307 K | $ 14.83 | -0.57 % | $ 2 B | USA |